NanJing Pharmaceutical Co Ltd
SSE:600713
NanJing Pharmaceutical Co Ltd
Operating Income
NanJing Pharmaceutical Co Ltd
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
NanJing Pharmaceutical Co Ltd
SSE:600713
|
Operating Income
¥1.5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
16%
|
CAGR 10-Years
22%
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Operating Income
¥22.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
16%
|
|
S
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Operating Income
¥8.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Operating Income
¥3.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
11%
|
CAGR 10-Years
18%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Operating Income
¥2.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
5%
|
CAGR 10-Years
21%
|
Huadong Medicine Co Ltd
SZSE:000963
|
Operating Income
¥3.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
See Also
What is NanJing Pharmaceutical Co Ltd's Operating Income?
Operating Income
1.5B
CNY
Based on the financial report for Sep 30, 2023, NanJing Pharmaceutical Co Ltd's Operating Income amounts to 1.5B CNY.
What is NanJing Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
22%
Over the last year, the Operating Income growth was 8%. The average annual Operating Income growth rates for NanJing Pharmaceutical Co Ltd have been 13% over the past three years , 16% over the past five years , and 22% over the past ten years .